AllianceBernstein’s Amylyx Pharmaceuticals AMLX Stock Holding History

AllianceBernstein’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$976K	Buy	80,800 +9,300	+13%	+$131K	﹤0.01%	2348
2025 Q4	$864K	Hold	71,500	–	–	﹤0.01%	2408
2025 Q3	$972K	Buy	71,500 +40,900	+134%	+$385K	﹤0.01%	2362
2025 Q2	$196K	Buy	+30,600	New	+$149K	﹤0.01%	3058
2024 Q2	–	Sell	-51,542	Closed	-$146K	–	3235
2024 Q1	$146K	Hold	51,542	–	–	﹤0.01%	2984
2023 Q4	$759K	Hold	51,542	–	–	﹤0.01%	2405
2023 Q3	$944K	Hold	51,542	–	–	﹤0.01%	2279
2023 Q2	$1.11M	Hold	51,542	–	–	﹤0.01%	2222
2023 Q1	$1.51M	Buy	51,542 +15,300	+42%	+$532K	﹤0.01%	2019
2022 Q4	$1.34M	Hold	36,242	–	–	﹤0.01%	2136
2022 Q3	$1.02M	Buy	36,242 +342	+1%	+$8.53K	﹤0.01%	2278
2022 Q2	$691K	Buy	+35,900	New	+$426K	﹤0.01%	2529

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

AllianceBernstein's AMLX Position: Q1 2026 in Review

AllianceBernstein increased its Amylyx Pharmaceuticals (AMLX) stake by 13% in Q1 2026, buying an estimated $131K and bringing the position to 80,800 shares worth $976K. The position accounts for ﹤0.01% of the portfolio, ranked #2348.

AllianceBernstein first reported a position in AMLX in Q2 2022 and has held it in 12 quarters since. The position peaked at $1.51M in Q1 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

AllianceBernstein held 80,800 shares of Amylyx Pharmaceuticals worth $976K as of Q1 2026.
AllianceBernstein bought 9,300 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $131K.
Amylyx Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2348 holding.
AllianceBernstein first reported a position in Amylyx Pharmaceuticals in Q2 2022 and has held it in 12 quarters since.
AllianceBernstein's Amylyx Pharmaceuticals position peaked at $1.51M in Q1 2023.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.